- Program
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Approach
BMC128
Combination Therapy with ICI for Solid Tumors
- Program
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Biological
Harnessing our computational analysis and predictive capabilities, we have identified BMC128, a rationally designed microbial consortium.
Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.